CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

STAT News
Original article

Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’

RegulatoryNeutral
AI Analysis

Summary

Compass Pathways CEO stated the company is prepared to proceed cautiously with its psychedelic therapy set for regulatory review this year. No specific drug name, indication, or FDA decision date was disclosed in the article.

Importance:3/10
Sentiment:
0.00
psychedelicsregulatory reviewCompass Pathways
Related Companies

Read the original article

Published by STAT News on October 15, 2026 12:01 AM

Read Original